Zusammenfassung
Das Mammakarzinom sowie das Endometriumkarzinom und das Ovarialkarzinom sind hormonabhängige Malignome. Östrogene und Gestagene können proliferativ auf das Tumorwachstum wirken. Die Hormontherapie (HT) in der Peri- und Postmenopause kann das Risiko für hormonabhängige Malignomerkrankungen erhöhen oder verringern. Dargestellt wird der Einfluss einer HT auf das Risiko für Mamma-, Endometrium-, Ovarial-, Zervix- und Kolorektalkarzinome.
Abstract
Breast, endometrial, and ovarian cancers are endocrine-dependent. Estrogens and progestogens can have a proliferative effect on tumor growth. Hormone therapy during and after menopause can raise or lower the risk of a malignoma. This article explains its influence on the risk of mammary, endometrial, ovarian, cervical, and colorectal cancers.
Literatur
Dietel M, Lewis MA, Shapiro S et al (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060. Epub 2005 Jun 2. Review
(n a) (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 350(9084):1047–1059. Erratum in: Lancet 1997 Nov 15;350(9089):1484
Rossouw JE, Anderson GL, Prentice RL et al (2002) Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
Heiss G, Wallace R, Anderson GL et al (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 9:1036–1045
Flesch-Janys D, Slanger T, Mutschelknauss E et al (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123(4):933–941
Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107(3):427–430. Epub 2007 Apr 24
Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427. Erratum in: Lancet. 2003 Oct 4;362(9390):1160
Kenemans P, Bundred NJ, Foidart JM et al on behalf of the LIBERATE Study Group (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-bline randomised, non inferiority trial. Lancet Oncol 10(2):135–146
Green PK, Weiss NS, McKnight B et al (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7(6):575–580
Ortmann O, König K (2005) Hormontherapie im Klimakterium und in der Postmenopause. Dtsch Arztebl 102(Heft 3):144–147
Hulley S, Furberg C, Barret-Connor E et al (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):58–66
Beral V, Bull D, Reeves G et al (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551
Doherty JA, Cushing-Haugen KL, Saltzman BS et al (2007) Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 197(2):139.e1–e7
Creasman WT, Henderson D, Hinshaw W et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326–330
Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189–191
Committee on Gynecologic Practice (2001) Hormone replacement therapy in women treated for endometrial cancer. Int J Gynecol Obstet 73:283–284
IARC Monographs Vol. 91 Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. Genf. ISBN 978 92 832 1291 1
Hunt K, Coleman MP (1987) The completeness of cancer registration in follow-up studies – a cautionary note. Br J Cancer 56(3):357–359
Anderson GL, Judd HL, Kaunitz AM et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748
Lancey JV, Brinton LA, Leitzmann MF et al (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405
Greiser CM, Greiser EM, Dören M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5):453–463. Epub 2007 Jun 15. Review
Beral V, Million Women Study Collaborators, Bull D, Green J et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710
Eeles RA, Tan S, Wiltshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302(6771):259–262
Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907–2915
McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 65(6):1201–1207. Review. No abstract available
Nanda K, Bastian LA, Hasselblad V et al (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93(5 Pt 2):880–888
Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004
Fournier A, Fabre A, Mesrine S et al (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26(8):1260–1268
Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–5787
Hormontherapie in der Peri-und Postmenopause (HT) Interdiziplinäre S3-Leitlinie AWMF 015/062
Delellis Henderson K, Duan L, Sullivan-Halley J et al (2010) Menopausal hormone therapy use and risk of invasive colon cancer: the California teachers study. Am J Epidemiol
Interessenkonflikt
Keine Angaben
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noss, D., Ortmann, O. Hormontherapie in der Peri- und Postmenopause. Gynäkologe 43, 318–323 (2010). https://doi.org/10.1007/s00129-009-2470-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-009-2470-3